Immunomodulators and Biologics: Beyond Stepped-Care Therapy

Mauli Desai; John Oppenheimer; David M. Lang

doi:10.1016/j.ccm.2018.10.011

Immunomodulators and Biologics: Beyond Stepped-Care Therapy

Mauli Desai, John Oppenheimer, David M. Lang

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

This review highlights recent data concerning efficacy and safety of biological agents that are currently approved by Food and Drug Administration (FDA), as well as several agents that will likely soon be FDA approved, for management of properly selected patients with severe persistent asthma that is poorly or not well controlled despite “stepped care” management according to best evidence.

Original language	English
Pages (from-to)	179-192
Number of pages	14
Journal	Clinics in Chest Medicine
Volume	40
Issue number	1
DOIs	https://doi.org/10.1016/j.ccm.2018.10.011
State	Published - Mar 2019

Keywords

Asthma
Benralizumab
Dupilumab
Mepolizumab
Omalizumab
Reslizumab

Access to Document

10.1016/j.ccm.2018.10.011

Cite this

@article{2711869e1c7e4171b4664801485bb92a,

title = "Immunomodulators and Biologics: Beyond Stepped-Care Therapy",

abstract = "This review highlights recent data concerning efficacy and safety of biological agents that are currently approved by Food and Drug Administration (FDA), as well as several agents that will likely soon be FDA approved, for management of properly selected patients with severe persistent asthma that is poorly or not well controlled despite “stepped care” management according to best evidence.",

keywords = "Asthma, Benralizumab, Dupilumab, Mepolizumab, Omalizumab, Reslizumab",

author = "Mauli Desai and John Oppenheimer and Lang, {David M.}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = mar,

doi = "10.1016/j.ccm.2018.10.011",

language = "English",

volume = "40",

pages = "179--192",

journal = "Clinics in Chest Medicine",

issn = "0272-5231",

publisher = "W.B. Saunders",

number = "1",

}

TY - JOUR

T1 - Immunomodulators and Biologics

T2 - Beyond Stepped-Care Therapy

AU - Desai, Mauli

AU - Oppenheimer, John

AU - Lang, David M.

PY - 2019/3

Y1 - 2019/3

N2 - This review highlights recent data concerning efficacy and safety of biological agents that are currently approved by Food and Drug Administration (FDA), as well as several agents that will likely soon be FDA approved, for management of properly selected patients with severe persistent asthma that is poorly or not well controlled despite “stepped care” management according to best evidence.

AB - This review highlights recent data concerning efficacy and safety of biological agents that are currently approved by Food and Drug Administration (FDA), as well as several agents that will likely soon be FDA approved, for management of properly selected patients with severe persistent asthma that is poorly or not well controlled despite “stepped care” management according to best evidence.

KW - Asthma

KW - Benralizumab

KW - Dupilumab

KW - Mepolizumab

KW - Omalizumab

KW - Reslizumab

UR - http://www.scopus.com/inward/record.url?scp=85060478902&partnerID=8YFLogxK

U2 - 10.1016/j.ccm.2018.10.011

DO - 10.1016/j.ccm.2018.10.011

M3 - Review article

C2 - 30691711

AN - SCOPUS:85060478902

SN - 0272-5231

VL - 40

SP - 179

EP - 192

JO - Clinics in Chest Medicine

JF - Clinics in Chest Medicine

IS - 1

ER -

Immunomodulators and Biologics: Beyond Stepped-Care Therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this